中轴型脊柱关节炎的新治疗靶点
本文综述中轴型脊柱关节炎(axSpA)的治疗靶点进展:TNF阻滞剂高效,而传统DMARDs及靶向IL-1、IL-6和T细胞的生物制剂无效;IL-23和IL-17成为新靶点,ustekinumab开放标签试验显示对AS有效,secukinumab两项安慰剂对照3期试验显示疾病活动度降低与TNF阻滞剂相似;新骨形成是潜在治疗靶点,但近期NSAID试验未能确认既往报告的抑制效应。
要点
- TNF阻滞剂对活动性axSpA高效,传统DMARDs及靶向IL-1、IL-6、T细胞的生物制剂无效
- IL-17抑制剂secukinumab在两项3期试验中降低疾病活动度,效果与TNF阻滞剂相似
- 新骨形成是AS潜在治疗靶点,但近期NSAID试验未确认既往抑制效应
核心结论
- IL-23和IL-17是axSpA有前景的新治疗靶点,IL-17抑制剂secukinumab的疗效与TNF阻滞剂相似。
研究设计与样本
- 综述类文章,未报告系统检索范围与样本量。
主要发现
- ustekinumab开放标签试验显示对AS患者疗效良好。
- secukinumab两项安慰剂对照3期试验显示疾病活动度降低,与TNF阻滞剂相似。
- 传统DMARDs及靶向IL-1、IL-6和T细胞(abatacept)的生物制剂对axSpA无效。
- 近期NSAID试验未能确认既往报告的NSAID对新骨形成的抑制效应。
临床怎么用
- 活动性axSpA可优先考虑TNF阻滞剂;IL-17抑制剂secukinumab为疗效相似的新选择。
- 不应使用传统DMARDs或靶向IL-1、IL-6、T细胞的生物制剂治疗活动性axSpA。
局限性
- 综述未报告系统检索策略、纳入研究数量及偏倚风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Axial spondyloarthritis (axSpA) patients can be divided into those with structural damage in the SI joint visible on X-rays, termed radiographic axSpA or AS, and those in an earlier phase of the disease, without structural damage in the SI joint, termed non-radiographic axSpA. TNF-blockers have been shown to be highly effective in the treatment of active axSpA. Interestingly, conventional DMARDs and also non-TNF-blocker biologics targeting IL-1, IL-6 and T cells (abatacept) are not effective. Recent interest has focused on the cytokines IL-23 and IL-17 as potential treatment targets in axSpA. An open-label trial with ustekinumab showed a good efficacy in AS patients. Two placebo-controlled phase 3 trials with a mAb blocking IL-17, secukinumab, showed a good reduction in disease activity, similar to that shown for TNF blockers. Probably triggered by inflammation, new bone formation is another hallmark in AS and a potentially important treatment target. However, a previously reported inhibitory effect of NSAID treatment could not be confirmed in a recent NSAID trial.
引用
- Sieper J. New treatment targets for axial spondyloarthritis. Rheumatology (Oxford). 2016. PMID: 27856659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。